Determinants of TB control, relapse and reinfection
Determinants of TB control, relapse and reinfection
批准号:
10430221
负责人:
SABINE EHRT
金额:
$258.33万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-04-30
关键词:
AddressAftercareAntibiotic TherapyAntibioticsAntimycobacterial AgentsAntitubercular AntibioticsBacillusBacteriaBiological MarkersBlood specimenBody FluidsCellsChemotherapy-Oncologic ProcedureClinicalClinical DataClinical MicrobiologyCountryDiseaseDrug KineticsEnrollmentFailureFamilyGenesGeneticGoalsGrowthHaitiHumanHuman GeneticsImmuneImmune systemImmunologicsImmunophenotypingInfectionInfection ControlIntegration Host FactorsKnowledgeLengthMachine LearningMaintenanceMeasuresMediatingModelingMouse StrainsMusMycobacterium tuberculosisOrganPatientsPersonsPharmaceutical PreparationsPharmacologyPlasmaPopulationPredispositionProcessRecurrenceRelapseResearch PersonnelResolutionResourcesRoleSamplingSampling StudiesShipsSiblingsSterilizationTYK2TestingTissuesTreatment outcomeTuberculosisWorkchemotherapeutic agentchemotherapychronic infectionclinical research sitecohortdata managementdesigndisorder later incidence preventionexperiencegenetic variantglobal healthgut microbiomehigh dimensionalityhigh riskimmunopathologyinsightmicrobiomemicrobiome compositionmicrobiome researchmouse modelnext generation sequencingpathogenpressurerecruitrelapse riskresponsesuccesssynergismtranscriptomicstreatment responsetuberculosis chemotherapytuberculosis drugstuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), continues to be a severe global
health problem. TB is multifaceted, but a central clinical and microbiologic feature of the disease is the ability of
Mtb to resist complete elimination, both by the host immune system and by chemotherapeutic agents with potent
growth inhibitory activity. This persistence in the face of immunologic and antibiotic pressure underlies several
important facets of TB disease, including 1) the existence of latent tuberculosis infection (LTBI) and, in the setting
of immunologic failure of LTBI control, its role in the genesis of active TB and 2) the prolonged course of TB
antibiotic therapy, which requires 6 months of multidrug therapy to achieve reliable clinical cure. Rather than
producing complete bacterial eradication in all treated subjects, cure following TB chemotherapy is now
understood to be an antibiotic induced paucibacillary state in which prevention of relapse depends in part on
poorly understood host factors. The host and bacterial determinants that mediate these two interrelated types of
persistence are only partially understood, a knowledge gap the Tri-I-TBRU aims to fill. We propose a set of 3
intersecting projects and 3 cores all focused on different facets of the problem of paucibacillary TB, both post
treatment and LTBI. The projects will use samples and clinical data from TB cohorts at our clinical site at
GHESKIO in Port Au Prince Haiti, to examine the immunologic, microbiomic, transcriptomic, pharmacokinetic,
and genetic factors that influence or predict the transition points between paucibacillary states of TB disease and
active transmissible infection. These human studies will be compared and contrasted with a new mouse model
of paucibacillary infection that will allow us to test mechanistic hypotheses about the host and bacterial
determinants of paucibacillary disease. This work with be conducted by a team of highly collaborative
investigators who have who have worked well together for several years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
M. tuberculosis carbon metabolism during infection
-
批准号:10716619
-
项目类别:
-
资助金额:$65.23万
-
财政年份:2023
-
负责人:SABINE EHRT
-
依托单位:
Tri-Institutional TRAC Basic Science Core
-
批准号:10430741
-
项目类别:
-
资助金额:$22.33万
-
财政年份:2022
-
负责人:SABINE EHRT
-
依托单位:
Tri-Institutional TRAC Basic Science Core
-
批准号:10675748
-
项目类别:
-
资助金额:$18.39万
-
财政年份:2022
-
负责人:SABINE EHRT
-
依托单位:
Turning Mycobacterium tuberculosis appetite for fatty acids against itself
-
批准号:10592602
-
项目类别:
-
资助金额:$21.19万
-
财政年份:2022
-
负责人:SABINE EHRT
-
依托单位:
Determinants of TB control, relapse and reinfection
-
批准号:10268801
-
项目类别:
-
资助金额:$275.55万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Determinants of TB control, relapse and reinfection
-
批准号:10621299
-
项目类别:
-
资助金额:$256.5万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Admin Core
-
批准号:10268802
-
项目类别:
-
资助金额:$14.12万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Determinants of Paucibacillary Mtb Infection in Mice
-
批准号:10430228
-
项目类别:
-
资助金额:$57.25万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Determinants of Paucibacillary Mtb Infection in Mice
-
批准号:10621309
-
项目类别:
-
资助金额:$45.82万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Determinants of Paucibacillary Mtb Infection in Mice
-
批准号:10268807
-
项目类别:
-
资助金额:$45.99万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Admin Core
-
批准号:10430222
-
项目类别:
-
资助金额:$18.43万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Microbiome in TB treatment response and disease resolution
-
批准号:10430225
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Microbiome in TB treatment response and disease resolution
-
批准号:10268805
-
项目类别:
-
资助金额:$54.7万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Admin Core
-
批准号:10621300
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Microbiome in TB treatment response and disease resolution
-
批准号:10621304
-
项目类别:
-
资助金额:$48.48万
-
财政年份:2021
-
负责人:SABINE EHRT
-
依托单位:
Project 1. Metabolic adaptations required for growth and virulence of Mtb at acidic pH.
-
批准号:10426179
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2020
-
负责人:SABINE EHRT
-
依托单位:
Core D. Administration Core
-
批准号:10426175
-
项目类别:
-
资助金额:$6.34万
-
财政年份:2020
-
负责人:SABINE EHRT
-
依托单位:
Project 1. Metabolic adaptations required for growth and virulence of Mtb at acidic pH.
-
批准号:10641874
-
项目类别:
-
资助金额:$28.77万
-
财政年份:2020
-
负责人:SABINE EHRT
-
依托单位:
Project 4. Defining cell division pathways in Mtb.
-
批准号:10641888
-
项目类别:
-
资助金额:$66.87万
-
财政年份:2020
-
负责人:SABINE EHRT
-
依托单位:
Project 3. Defining the RNA processing and degradation pathways of Mtb.
-
批准号:10426181
-
项目类别:
-
资助金额:$42.93万
-
财政年份:2020
-
负责人:SABINE EHRT
-
依托单位:
海外基金